Keywords: Multiple Sclerosis, Multiple Sclerosis
Motivation: Prior research showed 40% of MS patients have cortical gray matter hypoxia, with similar findings in EAE mouse models linked to reduced cerebral blood flow.
Goal(s): To determine if the vascular-protective drug eplerenone can restore cerebral blood flow in the EAE mouse model of MS.
Approach: EAE was induced in mice receiving either 50mg/kg or 100mg/kg eplerenone. Cerebral blood flow was measured using continuous arterial spin labeling MRI at 9.4T.
Results: High dose eplerenone (100mg/kg) prevented reduction in cortical cerebral blood flow and improved clinical scores, while the lower dose showed no effects.
Impact: These findings suggest early treatment with mineralocorticoid receptor antagonists could prevent vascular dysfunction in MS patients, potentially avoiding cortical hypoxia. This introduces a new therapeutic approach targeting blood flow regulation rather than traditional immunomodulation strategies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords